# US 2022/0031706 A1 · Trpc ion channel inhibitors for use in therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031706 A1
- Document ID: US20220031706A1
- Status: Published application
- Kind: A1
- Application number: 17/451,148
- Filed: 2021-10-15
- Published: 2022-02-03
- Earliest claimed: 2017-02-09
- Assignees: University of Leeds
- Applicants: University of Leeds
- Inventors: David John BEECH; Richard James FOSTER; Sin Ying CHEUNG; Baptiste Michel RODE
- Web page: https://patentgrep.com/patent/US20220031706A1

## CPC

- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07D 235/14: Radicals substituted by nitrogen atoms (by nitro radicals C07D235/10)
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G01N 2800/044: Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Described herein are inhibitors Transient Receptor Potential Canonical (TRPC) ion channels comprising TRPC4 protein and/or TRPC5 protein for use in combating obesity and other medical conditions including insulin resistance associated with Type II diabetes or development of Type II diabetes (pre-diabetes), metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Also disclosed is the use of the inhibitors for cosmetic purposes, such as cosmetic weight loss.

## Claims

### Claim 1

A method of treatment or prophylaxis of a condition selected from obesity, insulin resistance, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in a subject in need thereof, the method comprising administering to the subject an inhibitor which directly targets a Transient Receptor Potential Canonical (TRPC) ion channel comprising TRPC4 as present in adipocytes.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the TRPC4 ion channel further comprises TRPC1.

### Claim 5 (depends on 1)

The method of claim 1, wherein the inhibitor directly inhibits the expression or function of TRPC4.

### Claim 6 (depends on 1)

The method of claim 1, wherein the condition is obesity.

### Claim 7 (depends on 1)

The method of claim 1, wherein the condition is insulin resistance in a subject.

### Claim 8 (depends on 7)

The method of claim 7, wherein the subject is obese.

### Claim 9 (depends on 7)

The method of claim 7 wherein the insulin resistance is associated with Type II diabetes or prediabetes.

### Claim 10 (depends on 1)

The method of claim 1, wherein the condition is metabolic syndrome.

### Claim 11 (depends on 10)

The method of claim 10, wherein the treatment of metabolic syndrome comprises reducing abdominal obesity and/or reducing fasting blood glucose concentration.

### Claim 12 (depends on 1)

The method of claim 1, wherein the inhibitor is administered to a subject predetermined to have an elevated level in adipose tissue relative to TRPC4 mRNA and/or protein.

### Claim 13 (depends on 12)

The method of identifying a subject according to claim 12, which comprises:
a. determining the level of TRPC4 mRNA and/or protein in a sample of adipose tissue from a subject; and
b. selecting said subject for administration of the inhibitor if the level of said screening target exceeds a control level.

### Claim 14 (depends on 1)

The method of claim 1, wherein the inhibitor is an antibody or an antigen-binding fragment thereof.

### Claim 15 (depends on 14)

The method of claim 14 wherein said antibody binds TRPC4.

### Claim 16 (depends on 1)

The method of claim 1 wherein the inhibitor is a siRNA or antisense oligonucleotide.

### Claim 17 (depends on 16)

The method of claim 16 wherein the inhibitor inhibits expression of TRPC4 protein.

### Claim 18 (depends on 1)

The method of claim 1, wherein the inhibitor is a small molecule of 2000 daltons or less.

### Claim 19 (depends on 18)

The method of claim 18, wherein the inhibitor is a compound of the Formula (II), or a pharmaceutically acceptable salt thereof:
wherein:
R1 is C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which is optionally substituted with 1-4 R5;
R2 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halo, C1-6 haloalkoxy, hydroxyl, C1-6 alkoxy, C3-7 cycloalkyloxy, C6-10 aryl, C6-10 aryloxy, C7-16 arylalkoxy, amino, C1-6 akylamino, C2-12 dialkylamino, —S(O)xR′ (wherein x is 0, 1 or 2 and each R′ is independently H or C1-6 alkyl), heterocycloalkyl, heteroaryl, heteroaryloxy, —S(O)2NR′R′, wherein each R′ is independently H or C1-6 alkyl, —C(O)NR′R′, wherein each R′ is independently H or C1-6 alkyl, —NR′C(O)NR′R′, wherein each R′ is independently H or C1-6 alkyl, —S(O)2NR′C(O)NR′R′, wherein each R′ is independently H or C1-6 alkyl, —C(O)R′, wherein R′ is H or C1-6 alkyl, nitro, cyano, wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6haloalkoxy, hydroxyl, C1-6 alkoxy, C3-7 cycloalkyloxy, C6-10 aryl, C6-10 aryloxy, C7-16 arylalkoxy, amino, C1-6 akylamino, C2-12 dialkylamino, —S(O)xR′, heterocycloalkyl, heteroaryl, heteroaryloxy, —S(O)2NR′R′, wherein each R′ is independently H or C1-6 alkyl, C(O)NR′R′, wherein each R′ is independently H or C1-6 alkyl, —NR′C(O)NR′R′, wherein each R′ is independently H or C1-6 alkyl, —S(O)2NR′C(O)NR′R′, wherein each R′ is independently H or C1-6 alkyl, —C(O)R′, wherein R′ is H or C1-6 alkyl, is optionally substituted with 1-3 R6;
R3 is C1-6 alkyl, C3-7 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C2-6 hydroxyalkyl, or C1-6 alkoxy, each of which is optionally substituted with 1-4 R7;
R4 is C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which is optionally substituted with 1-4 R8;
R5, R6, R7, and R8 are each independently hydrogen, C1-6 alkyl, halo, C1-6 haloalkyl, C1-6 haloalkoxy, hydroxyl, C1-6 alkoxy, amino, C1-6 alkylamino, C2-12 dialkylamino, cyano, nitro, —C(O)NR′R′, wherein each R′ is independently H or C1-6 alkyl, —S(O)xR′ (wherein x is 0, 1 or 2), —C(O)OR′, —C(O)R′, C3-7 cycloalkyl, C6-10 aryl, heterocycloalkyl, or heteroaryl, wherein each R′ is independently H or C1-6 alkyl,
wherein each of C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, hydroxyl, C1-6 alkoxy, amino, C1-6 alkylamino, C2-12 dialkylamino, —C(O)NR′R′, wherein each R′ is independently H or C1-6 alkyl, —C(O)O—C1-6 alkyl, C3-7 cycloalkyl, C6-10 aryl, heterocycloalkyl, or heteroaryl is optionally substituted with 1-3 R9; and
each R9 is independently C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, heterocycloalkyl, C6-10 aryl, heteroaryl, C4-10 cycloalkylalkyl, heterocycloalkyl-C1-6 alkyl, C7-16 arylalkyl, heteroaryl-C1-6 alkyl, halo, hydroxyl, C1-6 alkoxy, C6-10 aryloxy, C7-16 arylalkoxy, C2-8 alkoxyalkoxy, amino, C1-6 akylamino, C2-12 dialkylamino, C1-6 alkyl-amino-C1-6 alkyl, C1-6 alkyl-amino-C2-12 dialkyl, —S(O)xR′ (wherein x is 0, 1 or 2), —S(O)2NR′R′, wherein each R′ is independently H or C1-6 alkyl, —C(O)NR′R′, wherein each R′ is independently H or C1-6 alkyl, —NR′C(O)NR′R′, wherein each R′ is independently H or C1-6 alkyl, —S(O)2NR′C(O)NR′R′, wherein each R′ is independently H or C1-6 alkyl, —C(O)R′, wherein R′ is H or C1-6 alkyl, —C(O)—C1-6 alkyl, —C(O)—C6-10 aryl, —NHC(O)—C1-4 alkyl, —NHC(O)—C6-10 aryl, —C(O)NR′R′, —C(O)NH—C6-10 aryl, —C(O)OR′, —OC(O)R′, nitro, or cyano;
wherein a “heterocycloalkyl” group comprises a non-aromatic saturated or partially saturated monocyclic heterocyclic ring system(s) containing from about 3 to 12 ring atoms, with from 1 to 5 heteroatoms selected from nitrogen, oxygen or sulfur in the ring;
wherein a “heteroaryl” group comprises monocyclic and bicyclic groups containing from five to twelve ring members, wherein each ring may contain up to four heteroatoms selected from nitrogen, sulfur and oxygen;
wherein “heteroaryloxy” group comprises a heteroaryl group covalently attached to —O—.

### Claim 20 (depends on 19)

The method of claim 19, wherein the inhibitor is:
or pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 19)

The method of claim 19, wherein the inhibitor is:
or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 18)

The method of claim 18, wherein the inhibitor is
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 16)

The method of claim 16, wherein the inhibitor is a compound of the formula (X), or a pharmaceutically acceptable salt thereof:
wherein R1 and R2 are independently H or C1-4 alkyl.

### Claim 24 (depends on 23)

The method of claim 23, wherein the inhibitor is a compound of formula (Xa):
or a pharmaceutically acceptable salt thereof.

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

A cosmetic method of reducing or inhibiting excess weight gain in a subject in need thereof, the method comprising administering to the subject an inhibitor which directly targets a Transient Receptor Potential Canonical (TRPC) ion channel comprising TRPC4 as present in adipocytes.

### Claim 28

(canceled)
